Hepion Pharmaceuticals adds two new directors

Hepion Pharmaceuticals, Inc. reported that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. reported that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026. This expands the company’s board and adds new oversight at the corporate level.

The filing notes there are no arrangements or understandings with other persons related to their selection, and no family relationships among the new directors and other company figures, except that Gary S. Stetz, II is the son of Interim Chief Executive Officer Gary Stetz.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Board appointment effective date: July 1, 2026 Par value of common stock: $0.0001 per share Trading symbol: HEPA

3 metrics

Board appointment effective date July 1, 2026 Effective date for appointments of Danina Fisher and Gary S. Stetz, II as directors

Par value of common stock $0.0001 per share Par value of Hepion Pharmaceuticals common stock registered under Section 12(b)

Trading symbol HEPA Ticker symbol for Hepion Pharmaceuticals common stock on the OTC market

Key Terms

Emerging growth company, Board of Directors, principal executive offices, Section 12(b) of the Act

4 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Board of Directors financial

"the Board of Directors of Hepion Pharmaceuticals, Inc."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

principal executive offices regulatory

"(Address of principal executive offices)"

Section 12(b) of the Act regulatory

"Securities registered pursuant to Section 12(b) of the Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change to Hepion Pharmaceuticals (HEPA) leadership was disclosed?

Hepion Pharmaceuticals disclosed that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026. This expands board membership and updates the company’s governance structure with two additional members.

Who are the new directors joining Hepion Pharmaceuticals (HEPA)?

The new directors are Danina Fisher and Gary S. Stetz, II. They were approved by the Board of Directors and their appointments became effective immediately on July 1, 2026, according to the company’s current report.

Are there any family relationships involving Hepion’s new directors?

Yes. The filing states there is no family relationship among the new directors and others at the company, except that Gary S. Stetz, II is the son of Interim Chief Executive Officer Gary Stetz, creating a disclosed familial link at the leadership level.

Were any special arrangements involved in selecting Hepion’s new directors?

The company states there are no arrangements or understandings between Danina Fisher or Gary S. Stetz, II and any other person pursuant to which they were selected as directors. Their appointments were approved by the Board without disclosed side agreements.

What is Hepion Pharmaceuticals’ trading symbol and market?

Hepion Pharmaceuticals’ common stock trades under the symbol HEPA on the OTC market. The filing identifies the security as common stock with a par value of $0.0001 per share registered under Section 12(b) of the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/02/2026 - 04:30 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1, 2026

Hepion Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36856

46-2783806

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(IRS

Identification No.)

34 Shrewsbury Ave., Suite 1C

Red Bank, NJ 07701

(Address of principal executive offices)

(732) 902-4000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock, par value $0.0001 per share		HEPA		OTC QB

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 1, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of Danina Fisher and Gary S. Stetz, II as directors of the Company, effective immediately.

There are no arrangements or understandings between Ms. Fisher and Mr. Stetz and any other person pursuant to which such person was selected as a director of the Company, and there is no family relationship between any of Ms. Fisher and Mr. Stetz, except that Mr. Stetz is Gary Stetz’s son.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 2, 2026		Hepion Pharmaceuticals, Inc.

	By:	/s/ Gary Stetz
		Gary Stetz
		Interim Chief Executive Officer

-3-

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents